Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 billion or ...
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively ...
DNA-binding proteins are proteins that bind to single- or double-stranded DNA, generally in the major groove if the binding is sequence-specific – as with transcription factors that regulate ...
Chart does not reflect overnight price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results